Baidu
map

Molecular Cell:复旦大学发表癌症研究新成果

2013-10-12 佚名 生物通

来自复旦大学、加州大学圣地亚哥分校和北卡罗来纳大学的研究人员证实,PKM2蛋白K433位点乙酰化可提高它的蛋白激酶活性和核定位,由此促进有丝分裂及癌变。这一研究发现发表在10月10日的《分子细胞》(Molecular Cell)杂志上。 【原文下载】 复旦大学的熊跃(Yue Xiong)教授、雷群英(Qun-Ying Lei)教授和加州大学圣地亚哥分校的管坤良(Kun-Liang Gu

来自复旦大学、加州大学圣地亚哥分校和北卡罗来纳大学的研究人员证实,PKM2蛋白K433位点乙酰化可提高它的蛋白激酶活性和核定位,由此促进有丝分裂及癌变。这一研究发现发表在10月10日的《分子细胞》(Molecular Cell)杂志上。 【原文下载】

复旦大学的熊跃(Yue Xiong)教授、雷群英(Qun-Ying Lei)教授和加州大学圣地亚哥分校的管坤良(Kun-Liang Guan)教授是这篇论文的共同通讯作者。熊跃教授主要研究方向是细胞周期、肿瘤抑制、蛋白泛素化、代谢调控、动物模式、人类疾病。雷群英教授研究方向为肿瘤代谢、Hippo-TAZ信号通路、蛋白质翻译后修饰调控机制及其生理病理效应等。管坤良教授则主要从事细胞生长调节及肿瘤细胞生物学的信号转导研究。

在哺乳动物细胞中,丙酮酸激酶存在PKM1、PKM2、PKL和PKR四种同工酶,根据组织不同的代谢功能,它们具有显著不同的调控机制与动力学特征。其中PKM1、PKM2是由PKM2基因编码,在转录过程中由前体mRNA经不同选择性剪接的产物,PKM1主要存在于成熟组织如脑组织与骨骼肌中;PKM2则主要存在与一些分化组织、具有核酸合成特性的细胞如胚胎细胞中。近年来的研究证实在肝癌、肺癌、乳腺癌、胰腺癌等许多的人类肿瘤细胞中均有PKM2高表达。PKM2是联系癌细胞微环境糖代谢、细胞生长信号和氧化应激的枢纽蛋白。

PKM2主要以高活性的四聚体和低活性的二聚体两种形式存在。四聚体形式,具有丙酮酸激酶活性,能催化磷酸烯醇式丙酮酸(PEP)转化为丙酮酸,与底物PEP有高亲和力,酶催化能力很强,为肿瘤细胞分化、增殖提供所需的能量。二聚体形式,尽管没有丙酮酸激酶活性,然而最近的研究表明其具有蛋白激酶的活性,能催化合成细胞构建模块如核酸、氨基酸、磷脂等。在癌细胞生长信号方面,癌症细胞PKM2的四聚体与二聚体存在动态平衡,受致癌蛋白P53、cMYC等、磷酸化、乙酰化和重要代谢中间体果糖1,6-二磷酸(FBP)等信号调控。在这篇文章中,研究人员证实PKM2可直接与它的变构激活剂FBP接触。p300乙酰基转移酶在PKM2独有的K433位点上使其乙酰化,通过干扰其与FBP结合可阻止PKM2激活,促进PKM2在细胞核中累积,提高它的蛋白激酶活性。研究人员发现,模拟乙酰化作用的PKM2(K433)突变体可促进细胞增殖和肿瘤形成。通过血清饥饿和细胞间接触可以降低K433乙酰化,而在乳腺癌中刺激细胞周期、表皮生长因子(EGF)和癌蛋白E7则可提高K433乙酰化及富集。

这些结果表明,K433乙酰化将PKM2从胞质代谢激酶切换为核蛋白激酶与细胞增殖和转化联系了起来。新研究发现揭示了肿瘤关键酶PKM2蛋白质的活性调控新机制,以及PKM2乙酰化修饰对于肿瘤发生发展的影响,从而为开发出靶向调控肿瘤的药物提供了新思路。


原文检索

Lei Lv, Yan-Ping Xu, Di Zhao, Fu-Long Li, Wei Wang, Naoya Sasaki, Ying Jiang, Xin Zhou, Ting-Ting Li, Kun-Liang Guan, Qun-Ying Lei,Yue Xiong.Mitogenic and Oncogenic Stimulation of K433 Acetylation Promotes PKM2 Protein Kinase Activity and Nuclear Localization.Molecular Cell 2013 October 10.  【原文下载】

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922137, encodeId=c1e1192213e4d, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Aug 02 13:58:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868689, encodeId=a28518686899b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Mar 30 13:58:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958928, encodeId=ee741958928df, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 19 01:58:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514119, encodeId=deee151411985, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538419, encodeId=d91115384196b, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
    2014-08-02 wgx306
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922137, encodeId=c1e1192213e4d, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Aug 02 13:58:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868689, encodeId=a28518686899b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Mar 30 13:58:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958928, encodeId=ee741958928df, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 19 01:58:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514119, encodeId=deee151411985, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538419, encodeId=d91115384196b, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1922137, encodeId=c1e1192213e4d, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Aug 02 13:58:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868689, encodeId=a28518686899b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Mar 30 13:58:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958928, encodeId=ee741958928df, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 19 01:58:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514119, encodeId=deee151411985, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538419, encodeId=d91115384196b, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
    2014-02-19 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922137, encodeId=c1e1192213e4d, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Aug 02 13:58:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868689, encodeId=a28518686899b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Mar 30 13:58:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958928, encodeId=ee741958928df, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 19 01:58:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514119, encodeId=deee151411985, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538419, encodeId=d91115384196b, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1922137, encodeId=c1e1192213e4d, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sat Aug 02 13:58:00 CST 2014, time=2014-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868689, encodeId=a28518686899b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Mar 30 13:58:00 CST 2014, time=2014-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1958928, encodeId=ee741958928df, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 19 01:58:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514119, encodeId=deee151411985, content=<a href='/topic/show?id=448ee1455a3' target=_blank style='color:#2F92EE;'>#癌症研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71455, encryptionId=448ee1455a3, topicName=癌症研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c410636799, createdName=小华子, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538419, encodeId=d91115384196b, content=<a href='/topic/show?id=751e42660f1' target=_blank style='color:#2F92EE;'>#复旦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42660, encryptionId=751e42660f1, topicName=复旦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6c312994908, createdName=saikp, createdTime=Mon Oct 14 01:58:00 CST 2013, time=2013-10-14, status=1, ipAttribution=)]
    2013-10-14 saikp

相关资讯

Nature Methods:基于基因组网络分层可能成为癌症分型新方法

肿瘤几乎从来就没有共享过完全相同的遗传突变,这使得人们为更好地将癌症类型分门别类、以及开发出更有效的靶向性治疗所付诸的科学努力面临困难重重。 现在,来自加州大学圣地亚哥分校研究人员提出了一种称作为基于网络分层(network-based stratification, NBS)的新方法,这种方法不是根据个体患者的异常突变,而是根据这些突变如何影响共享的遗传网络或系统来

Adv Mat & JACS:癌细胞捕获与释放研究取得新进展

癌细胞与材料表面的相互作用是生物界面化学研究中的前沿热点之一,对肿瘤诊断、抗癌药物筛选等研究具有重要意义。在国家自然科学基金委、科技部和中国科学院的大力支持下,中国科学院化学研究所有机固体重点实验室的科研人员,在生物界面上癌细胞的特异识别与粘附调控方面取得了重要进展。 受免疫细胞与肿瘤细胞的特异粘附界面启发,相关实验人员不再将细胞简化成理想的球体,而是还原其多尺度性,提出了结构匹配和分子识别的协

PLoS One:新研究证明血液测试能检测癌转移

来自德国哥廷根大学兽医学研究所和美国Chronix生物医学公司的科研人员发表了一项探索犬乳腺癌的遗传标记的新的研究。发表在同行评审的《公共科学图书馆 综合》(PLOS ONE)杂志上的这篇论文识别出了人类和犬乳腺肿瘤的重要相似之处和差别,为使用犬模型系统的未来研究提供了一个强有力的平台。 【原文下载】 作为该项目的一部分,这组科研人员成功地实施了Chronix生物医学公司的检测见于血液无

Nat Genet:人类癌症的致癌全景图

用于新型癌症治疗方法的临床试验设计,一般来说都是集中在肿瘤起源所在的组织,然而近期由纪念斯隆-凯特琳癌症中心的研究人员完成的一项研究则发现了一种新的方法:基于基因组标记进行研究,而不是针对机体器官组织进行研究。 这一研究成果公布在9月26日的Nature Genetics杂志上,同时还有多篇文章将陆续发布于各大期刊杂志。这些成果利用了来自癌症基因组图集(Cancer Genome Atlas,T

Science:在“垃圾DNA”中发现潜在癌症病源

人类基因组中仅有 1% 到 2% 的是负责蛋白质编码的基因,其余非编码区域早先被认为是毫无用处的“垃圾 DNA”。但是,美、英等国研究人员最近在这个“垃圾”区域中找到近百个乳腺癌与前列腺癌的潜在“导火索”,显示了研究“垃圾 DNA”对了解癌症的重要性。 【原文下载】 美国耶鲁大学、英国韦尔科姆基金会桑格研究所(Wellcome Trust Sanger Institute)等机构的研究人员3日在

Molecular Cell:癌症生长转移新机制

来自哥本哈根大学的研究人员获得了对于癌细胞生长和转移极为重要的一些分子机制更深入的认识。他们的研究目的旨在研发出改良的、更具靶向性的药物。这些研究结果发表在近期的《分子细胞》(Molecular Cell)杂志上。 研究人员正不断地努力了解更多有关人体高等通讯过程的知识。作为细胞中的一种信号交换器,受体将一些特异的信号蛋白与特定的细胞功能连接起来。利用最先进的技术,哥

Baidu
map
Baidu
map
Baidu
map